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Background: The purpose of this study was to compare knowledge on the part of health 
workers in public and private health facilities about prescribing and dispensing of an 
  artemether-lumefantrine combination, 3 years after moving from sulfadoxine-pyrimethamine 
to artemether-lumefantrine as a first-line treatment for nonsevere malaria in Tanzania.
Methods: A cross-sectional survey of a convenience sample of 306 dispensaries and pharma-
cies was conducted in Dar Es Salaam and the Coast region of Tanzania. Of these, 122 were 
community pharmacies, 143 were private dispensaries, and 41 were public dispensaries. Specific 
outcome measures were health workers’ knowledge of the new malaria treatment guidelines, 
recommended doses of artemether-lumefantrine, and food requirements.
Results: A total of 489 health workers were included in the study. The respondents were pre-
scribers in private dispensaries, public dispensaries, and community pharmacies. Participants 
included medical officers (3.7%), clinical officers (38%), pharmacists (5.7%), and pharmaceutical 
technicians (3.9%). Nearly all workers in the public dispensaries and about 50% of workers in 
private dispensaries and community pharmacies were aware of recommended first-line malaria 
treatment. The difference in the proportion of health workers with adequate knowledge about 
the new recommended antimalarial medicine in public and private dispensaries was statistically 
significant (P , 0.0001). There was a higher proportion of workers in public dispensaries who 
had adequate knowledge about doses of artemether-lumefantrine for adults compared with work-
ers in private dispensaries (P = 0.001). Only 58.0% of respondents were able to state correctly 
the recommended doses in private dispensaries as compared with 77.0% in public dispensaries. 
Knowledge about the requirement for a concomitant fatty meal was not significantly different 
between workers in public and private dispensaries (P = 0.280) or between those working in 
public dispensaries and pharmacies (P = 0.622).
Conclusion: Knowledge about the use of artemether-lumefantrine was higher among health 
workers in public dispensaries than in their counterparts from private health care settings. The 
training organized by the Ministry of Health for workers in public health facilities in Tanzania 
contributed to such differences.
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Introduction
Countries severely hit by malaria changed their national drug policies and   introduced 
artemether-lumefantrine as first-line therapy for nonsevere Plasmodium falciparum 
malaria in 2006.1–5 Since the introduction of artemisinin-based combination therapy 
for malaria, substantial progress has been made in delivering these products to patients 
through the public health system, basically by the funding from the Global Fund, the 
US President’s Malaria Initiative, and the World Bank in many   African countries.6 Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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Currently, the artemether-lumefantrine combination is the 
treatment of choice for nonsevere and uncomplicated malaria.7,8 
Because of its considerably high price and concomitant food 
requirement, implementation of artemether-lumefantrine has 
encountered competition with some suboptimal nonartemether 
therapies like sulfadoxine-pyrimethamine.9–11 In developing 
countries like Tanzania, patients who seek treatment in private 
facilities cannot easily afford artemisinin-based combination 
therapy, so resort to cheaper less effective monotherapies.9,12,13 
In Tanzania, apart from artemether-lumefantrine, other 
artemisinin-based combinations and antimalarial drugs for 
monotherapy are widely available and easily accessed in pri-
vate health facilities.14–16 These include Duo-cotecxin® tablets 
(Zhejiang Holley Nanhu Pharmaceutical Co Ltd, Jiaxing, 
China), Artequin® tablets (Mepha Ltd, Aesch, Switzerland), 
Artequick® tablets (Artepharm Co, Ltd, Guangzhou, China), 
Co-Malafin® (Shelys Pharmaceuticals Ltd, Dar Es Salaam, 
Tanzania), Amobin® tablets (Regal Pharmaceuticals Ltd, Nai-
robi, Kenya), Ekelfin® tablets (Elys Chemical Industries Ltd, 
Nairobi, Kenya), Fansidar® tablets (Roche, Basel, Switzerland), 
and Halfan® tablets and/or syrup (GlaxoSmithKline, Essone, 
France). Quinine injection and tablets are available in all pri-
vate and public health facilities. Nonetheless, amodiaquine 
and sulfadoxine-pyrimethamine tablets and/or syrup are still 
present in both public and private health outlets.17
Today, despite substantial funding by donors and govern-
ment partners to support the implementation of these new 
treatment policies, very little is known about the extent to 
which health workers have implemented these changes in 
some countries. Policy implementation is a long process and 
can take several years to produce effective change.18–20 The 
steps involved include sensitization of health providers and 
the community, training of providers, issuing of directives (in 
terms of time limit) with regards to phasing out old medicines 
and full use of the newly introduced one, and directives on 
stocking, rational prescribing, and dispensing of the required 
medicines.18 Until now, published reports on health workers’ 
adherence to artemisinin-based combination treatment polices 
are only available for few countries.17,21–24 This study aimed 
at assessing the implementation of artemether-lumefantrine 
treatment in Tanzania by measuring knowledge among health 
workers about artemether-lumefantrine as a first-line malaria 
treatment, the correct doses, and the need for concomitant food 
intake 3 years after a policy change in this country.
Methods and materials
This was a prospective, cross-sectional, descriptive study 
conducted in community pharmacies and public and   private 
dispensaries in Dar Es Salaam and the Coast region of 
  Tanzania. The study took place in public and private health 
facilities because people in the community receive   treatment 
from both of these facilities. For effective treatment of 
malaria with first-line medicine after a policy change, it is 
important for all health providers to have some level of aware-
ness and knowledge about correct doses, irrespective of the 
nature of the health settings. The regions used in this survey 
were selected due to their similar geographical locations and 
climatic conditions. The regions are situated along the coast 
of the Indian Ocean, and the local people have similar out-
door activities. The study took place between January 2009 
and June 2009, and data were collected from both public 
and private health settings. A total of 489 health workers 
were included from three settings, ie, private pharmacies, 
and public and private dispensaries. The public and private 
dispensaries are all at the same level, hence there were no 
variations in staff qualifications or levels of care. The inclu-
sion criteria for dispensaries was whether the dispensary 
was private or public and whether it was accessible. Only 
pharmacy staff who consented to participate in the study were 
included. Both prescribers and dispensers were interviewed 
in public and private dispensaries. Only the dispensers were 
interviewed in the private pharmacies.
Data collection
Data were collected using structured questionnaires (see 
Appendix) and assessed knowledge among health workers 
about first-line malaria treatment, including the dosage regi-
men for artemether-lumefantrine in the different age groups 
and the need for concomitant food intake. The first set of 
questions investigated the qualifications of the participants, 
the category/level of each health facility, and awareness 
of first-line malaria treatment among respondents. Other 
questions assessed knowledge of the dosage regimen for 
the different age groups. Because of the requirement for 
fat ingestion to improve the bioavailability of artemether-
lumefantrine, there were questions assessing the knowledge 
of participants about this. Another set of questions asked 
whether participants received any kind of training concern-
ing current first-line and second-line malaria medicines. 
Examples of the last two questions included “Have you ever 
been given any formal training/health education on the use 
of artemether-lumefantrine?” and “In your opinion, what is 
currently the second-line drug for nonsevere malaria in Tan-
zania?” These questions were basically meant to determine 
whether participants received training on the current malaria 
treatment guidelines.Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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Table 1 characteristics of health facilities and health workers
Characteristics Frequency
Health facility category (n = 306)
community pharmacies 122 (39.8%)
Private dispensaries 143 (46.7%)
Public dispensaries 41 (13.4%)
Health workers qualifications (n = 489)
Clinical officers 186 (38.0%)
Medical officers 18 (3.7%)
nurse assistants 189 (38.6)
Pharmaceutical technician 19 (3.9%)
Pharmacists 28 (5.7%)
Registered nurses 49 (10.0%)
Data analysis
Data collected were coded and analyzed using the Statistical 
Package for Social Sciences, Version 15.0 software (SPSS Inc, 
Chicago, IL). Descriptive statistics were used to measure the 
relative frequencies of variables. Distribution of prevalence 
was analyzed using cross-tabulation and Chi-square tests.
Results
This study took place 3 years after implementation of the 
new artemether-lumefantrine treatment policy in Tanzania. 
In total, 489 health workers were interviewed (Table 1), com-
prising clinical officers (38.0%), nurse assistants (38.6%), 
pharmacists (5.7%), and medical officers (3.7%). Of the 
three different types of health facilities assessed, 39.8% were 
community pharmacies, 46.7% were private dispensaries, and 
13.4% were public dispensaries. Only 18.8% of respondents 
had received any formal training on how to use artemether-
lumefantrine since its introduction as a first line-treatment 
for malaria.
Awareness of new malaria treatment 
policy
Table 2 shows the proportion of health providers with knowl-
edge of first-line antimalarial drug treatment for nonsevere 
malaria after the changes in the treatment guidelines. Almost 
all (96.6%) respondents in public dispensaries knew about 
correct first-line malaria treatment as compared with their 
counterparts in private health settings, ie, private dispensaries 
and pharmacies (P , 0.0001). Similarly, more health workers 
(86.2%) in public dispensaries were able to cite quinine tab-
lets/intramuscular injections correctly as second-line malaria 
treatment than their colleagues in either private dispensaries 
or community pharmacies (P , 0.0001). The difference in 
awareness of first-line and second-line treatment among 
health workers in public and private health settings was 
Table 2 Knowledge of the new malaria treatment policy in health 
workers in different facilities
Health facility P value
Public 
dispensary 
n = 117
Private 
dispensary 
n = 244
Community 
pharmacy  
n = 119
First-line treatment with AL
Able to tell  
correctly
113 (96.6%) 111 (45.5%) – ,0.0001*
Able to tell  
correctly
113 (96.6%) – 62 (52.1%) ,0.0001*
second-line treatment (quinine)
Able to tell  
correctly
100 (86.2%) 149 (61.6%) – ,0.0001*
Able to tell  
correctly
100 (86.2%) – 46 (40.0%) ,0.0001*
Note: *Highly statistically significant. 
Abbreviation: AL, artemether-lumefantrine.
highly statistically significant. In private dispensaries, less 
than 50% of respondents could mention the recommended 
first-line malaria medicine. In community pharmacy, only 
40% of all respondents were able to mention correctly the 
second-line malaria medicine, ie, quinine.
Knowledge about doses
Table 3 shows the proportion of health workers in public 
dispensaries who were able to state the correct artemether-
lumefantrine doses in comparison with workers in private 
settings. Of the participants in public dispensaries, 77.0% 
were able to state correctly the recommended doses for adults 
as compared with 58.0% and 60.6% in private dispensaries 
and community pharmacies, respectively. This difference was 
statistically significant (P , 0.001). There was a statistically 
significant difference between public dispensaries and private 
dispensaries as well as community pharmacies on knowl-
edge about the doses in children from different age groups 
(Table 3). This was evident from the results, whereby 73.5% 
of participants in public dispensaries mentioned the correct 
doses for children with body weight of 5–14 kg, while less 
than 50% of participants in the private settings were able to 
do so (P , 0.0001).
Knowledge about food requirements
Table 4 shows the level of knowledge about the food require-
ment during malaria treatment with artemether-lumefantrine. 
As many as 63.8% of participants in public dispensaries, 
51.9% in private dispensaries, and 70.4% in community 
pharmacies responded correctly. However, very few provid-
ers in public and private settings knew that a fatty meal was Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Knowledge of artemether-lumefantrine doses in health workers according to body weight
Dose Health facility P value
Public 
dispensary
Private 
dispensary
Community 
pharmacy
Adult .35 kg n = 113 n = 212 n = 104
dose correctly 87 (77.0%) 123 (58.0%) – = 0.001**
stated dose correctly 87 (77.0%) – 63 (60.6%) = 0.009**
All children $5 kg n = 113 n = 206 n = 99
3 months to 3 years (5–14 kg)
stated dose correctly 83 (73.5%) 98 (47.6%) – ,0.0001*
stated dose correctly 83 (73.5%) – 44 (44.4%) ,0.0001*
3–8 years (1–24 kg)
stated dose correctly 83 (73.5%) 98 (47.6%) – ,0.0001*
stated dose correctly 83 (73.5%) – 41 (41.4%) ,0.0001*
8–12 years (25–35 kg)
stated dose correctly 83 (73.5%) 99 (48.1%) – ,0.0001*
stated dose correctly 83 (73.5%) – 42 (42.4%) ,0.0001*
Notes: *Highly statistically significant; **statistically significant.
Table 4 Knowledge of food requirement during artemether-lumefantrine therapy in health workers
Health facility P value
Public 
dispensary
Private 
dispensary
Community 
pharmacy
Knowledge of food requirement n = 116 n = 231 n = 115
before taking AL
said “yes” food is needed while taking AL 74 (63.8%) 119 (51.9%) – = 0.030**
said “yes” food is needed while taking AL 74 (63.8%) – 81 (70.4%) = 0.283***
Knowledge of type of food needed n = 73 n = 119 n = 79
stated “milk and/or fatty meal” 23 (31.5%) 29 (24.4%) – = 0.280***
stated “milk and/or fatty meal” 23 (31.5%) – 22 (27.8%) = 0.622***
Notes: **Statistically significant; ***not statistically significant. 
Abbreviation: AL, artemether-lumefantrine.
important for improving drug absorption (Table 4). The dif-
ference in responses amongst the health workers in public 
and private dispensaries on knowledge about the need for 
food during treatment with artemether-lumefantrine was 
not statistically significant (P = 0.030). The results compare 
the knowledge of participants in public dispensaries and 
community pharmacies about the food requirement before 
artemether-lumefantrine intake and indicates that there was 
no statistically significant difference (P = 0.622).
Discussion
This study compared knowledge on implementation of 
artemether-lumefantrine policy in malaria treatment in 
  Tanzania between health workers in public and private health 
care facilities.
The changes in policy from sulfadoxine-pyrimethamine 
to artemether-lumefantrine as a first-line antimalarial drug 
was officially announced at the end of 2006. Within 6 months, 
Minzi et al conducted a survey to assess if dispensers in private   
pharmacies had received any training on the   implementation of 
the treatment policy changes from chloroquine to sulfadoxine- 
pyrimethamine and from sulfadoxine-pyrimethamine to 
artemether-lumefantrine and showed that none of the partici-
pants were either involved in the preparation of the guidelines 
or trained on their implementation.25 The present study was 
conducted 3 years later and compared knowledge among 
health workers in public and private health settings about 
implementation of the artemether-lumefantrine treatment 
policy in uncomplicated P . falciparum malaria.
Our results indicated that only 18.8% of the interviewed 
health workers had received formal training on how to pre-
scribe and/or dispense artemether-lumefantrine. This propor-
tion is less than half that reported from Kenya where 46% of 
health workers received inservice training on artemether-lume-
fantrine.17 However, there is still a lot to be desired with regard 
to how preparation and implementation of new treatment 
guidelines is being handled in developing countries. Probably 
the best solution to increase the number of trained personnel Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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and reach nonqualified health workers is through training at 
least one health worker from each drug outlet who could in 
turn train colleagues in the workplace. Another approach is to 
provide adequate sensitization in the country before the policy 
is implemented.26,27 This study provides information on the 
qualifications of respondents (Table 1) whereby pharmaceuti-
cal personnel comprised only 9.6% and qualified prescribers 
(medical and clinical officers) comprised 41.7%. These are the 
health workers who are supposed to comprise the majority of 
dispensers in community pharmacies and prescribers in public 
and private dispensaries, respectively. It has been previously 
reported by Mugoyela and  Ally that dispensers lack sound 
knowledge on good pharmacy practice because of their training 
background and lack of regular access to health information 
provided by the regulatory body and other sources.28 This 
trend of an inadequate training background has been observed 
among prescribers and dispensers in the current study. In our 
study, we investigated awareness of health workers about first-
line and second-line malaria treatments. The results show a 
highly statistically significant difference in awareness between 
workers in public and private settings. Almost all (96.6%) 
participants in public dispensaries and less than 50% in private 
dispensaries and community pharmacies stated the first-line 
and second-line malaria treatment correctly. A very important 
observation made from these results is that the new treatment 
policy was prescribed mainly in public settings. In addition, 
the procurement of artemether-lumefantrine was included 
in the “WHO Model List of Essential Medicines” for adults 
and children, and Novartis, the manufacturer of artemether-
lumefantrine (Coartem®), and the World Health Organization 
in 2001 signed a memorandum of understanding to ensure that 
artemether-lumefantrine was available at cost price in malaria-
endemic areas.7 Indeed, in developing countries, global subsidy 
plays an important role in supplying artemether-lumefantrine 
in public health care facilities.29,30 Therefore, priority was 
given by the Ministries of Health to training health workers in 
public hospitals and dispensaries in various countries where 
artemether-lumefantrine is available.
Table 3 shows a highly statistically significant difference 
in knowledge between health workers about adult doses in 
public dispensaries as compared with workers in private health 
settings. The majority of respondents (77.0%) in public dis-
pensaries managed to state the adult doses correctly. Similarly, 
most of the health workers (73.5%) in public dispensaries 
stated doses for children correctly. In private health facilities, 
only 45% of respondents were able to state the pediatric doses 
correctly, although 60% managed to mention the right doses 
for adults. The high level of knowledge among health workers 
in public settings is partly the outcome of sensitization training 
by the Ministry of Health and reading of directions for use 
of the medicine on the labeling of packaged materials.22,25,31 
It has been reported in the literature that incorrect weight-
specific prescriptions of artemether-lumefantrine are rare, and 
blister packaging is likely to be a factor contributing to this 
level of knowledge.14,17 The six-dose regimen of artemether-
lumefantrine has proven to be highly effective when given 
at hours 0, 8, 24, 36, 48, and 60 of the treatment course.7,32 
For children, appropriate weight-adjusted doses are recom-
mended, so children   weighing $5/,15 kg, $15/,25 kg, 
and $25/,35 kg should be given one, two, and three tablets, 
respectively, per time point.7,19
In our study, we used artemether-lumefantrine available 
in packs with a weight-specific number of tablets, including 
pictorial instructions on how to use the medicine. For ease of 
use and rapid policy dissemination, all health workers should 
undergo training. In most of the developing countries, dur-
ing the change of policy to artemisinin-based combinations, 
only health workers in public health systems and very few 
in private health facilities were trained on how to dispense 
artemether-lumefantrine due to financial constrains.22,33 The 
outcome of lack of trained health workers responsible for 
handling the new introduced medicine as per guidelines 
could lead to administration of wrong doses and incorrect 
information being given to patients.
Oral absorption of artemether-lumefantrine is enhanced 
by concomitant consumption of fat-containing food,11,34 and 
it was recently reported that intake of soy milk enhances 
bioavailability of the drug.7,35 In our study, we found that the 
majority of respondents (.50%) in each health care facility 
stated that “food intake” is one of the necessary requirements 
for artemether-lumefantrine therapy (Table 4). However, the 
responses regarding type of food needed, ie, whether “milk 
or fatty meal”, was not statistically significant either between 
respondents in public and private dispensaries (P = 0.280) 
or between public dispensaries and community pharmacies 
(P = 0.622). Less than 50% respondents in each setting were 
able to mention this correctly. At the time we conducted this 
study, subsidized artemether-lumefantrine was only available 
in public health facilities. In the private health settings, 
other antimalarial medicines were available. For effective 
implementation of policy change for malaria treatment in 
developing countries, subsidized AL should be available both 
in public and private health facilities. Nonetheless, the avail-
ability of other malaria therapies should not be overlooked
Conclusion
Knowledge about the use of artemether-lumefantrine was 
higher among health workers in public dispensaries than Risk Management and Healthcare Policy 2011:4 submit your manuscript | www.dovepress.com
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in their counterparts in private health settings. Training 
organized by Ministry of Health for workers in public 
health facilities in Tanzania contributed to this difference in 
awareness. For effective implementation of the new treatment 
guidelines, training should be given to health workers in both 
public and private settings.
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Artemether-lumefantrine for malaria in Tanzania
Appendix Questionnaire used to interview health workers
  1. name of the interviewer_________
  2. serial number_________________
  3. name of the health facility_____________
  4. category of the health facility (tick appropriately)
    Public dispensary
    Private dispensary
    community pharmacy
  5. Qualifications of the respondent (tick)
      Pharmacist    Medical officer    Nurse assistant    Pharmaceutical technician    Clinical officer    Pharmaceutical attendant  
Registered nurse    Other (specify)________
  6. District name________________
  7.   Do you know that there have been changes in the recommendations for treating malaria?
    Tick Yes or nO
  8. if yes, do you know when it changed?_______________
  9.   Do you know which antimalarial drug is currently recommended for treating uncomplicated malaria?
10.   What dose of artemether-lumefantrine tablets do you prescribe/dispense to malaria patients?
    3 months to 3 years (4–14 kg)
    3 to 8 years (15–24 kg)
    8 to 12 years (25–35 kg)
    Adult . 35 kg
11.   Is there any food requirement which should be fulfilled by a patient before taking artemether-lumefantrine?
    Yes or nO
12. if yes please state the type of food required?
    Yes or nO
    if yes, mention how you know__________________
13. Have you ever been given any formal training/health education on the use of artemether-lumefantrine?
    Yes or nO
14. What is the second-line antimalarial drug in Tanzania? name______